Trevi Therapeutics(TRVI)

Focus: Trevi Therapeutics is a public biotech company focused on small-molecule therapeutics for respiratory, dermatology, and neurology indications. The company operates as a clinical-stage enterprise with a lean pipeline centered on nalbuphine ER formulations.

Unknown Respiratory Dermatology Neurology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Trevi Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Trevi Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

14 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Exoskeleton-Assisted Gait Training

Severe Stroke

N/A

Clinical Trials (1)

NCT03395717Stroke Rehabilitation With Exoskeleton-assisted Gait.

N/A

Help build intelligence for Trevi Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active clinical development with 14 ongoing trials across Phases 1-3, providing exposure to real-time trial progression and clinical decision-making
R&D investment growing 63% YoY ($24M in FY2024 to $39M in FY2025), signaling commitment to pipeline expansion despite losses
Focused therapeutic portfolio in high-need areas (uremic pruritus, prurigo nodolaris, IPF, chronic cough) with limited competition

Watch Out For

Pre-revenue biotech burning $47.9M annually with only $34M cash on hand creates 7-9 month runway; elevated dilution/financing risk
Minimal hiring velocity (only 6 active roles) and concentrated clinical ops focus suggest limited career mobility or department breadth
No marketed products, approved NDAs, or near-term PDUFA catalysts; all value contingent on Phase 2/3 trial success

Generated by Claude from Trevi Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Nalbuphine HCL ER

Uremic Pruritus

PHASE_1

Clinical Trials (1)

NCT02373215Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Phase 1

NAL ER

Healthy Participants

PHASE_1

Clinical Trials (2)

NCT07015398A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

Phase 1

NCT07487740A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

Phase 1

Nalbuphine ER

Nalbuphine

PHASE_1

Clinical Trials (1)

NCT04020016Study of Nalbuphine ER in Participants With Hepatic Impairment

Phase 1

NAL ER

Idiopathic Pulmonary Fibrosis

PHASE_1